News Related to Fibroblast Growth Factor Receptor 3

Related coverage linked through entity extraction aliases.

FDA Clears Abbisko's FGFR Inhibitor for Achondroplasia as BridgeBio Reports Phase 3 Success

Apr 01, 2026

The FDA has cleared Abbisko Therapeutics' IND application for ABSK061, an oral FGFR2/3 inhibitor for achondroplasia, while BridgeBio reports positive Phase 3 results for its oral infigratinib in the same condition. Both companies are advancing oral therapies targeting FGFR3 overactivity in this genetic growth disorder.

Two therapies show growth gains for children with achondroplasia

Mar 10, 2026

The FDA approved navepegritide, a once-weekly injectable therapy for achondroplasia, while phase 3 data showed infigratinib, an investigational oral medication, achieved the highest growth velocity reported in randomized trials for the condition.